Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Deferred Taxes (2016 - 2018)

Spero Therapeutics (SPRO) has disclosed Deferred Taxes for 3 consecutive years, with $645000.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Deferred Taxes rose 2054.55% year-over-year to $645000.0, compared with a TTM value of $554000.0 through Dec 2018, up 532.81%, and an annual FY2018 reading of $554000.0, up 532.81% over the prior year.
  • Deferred Taxes was $645000.0 for Q4 2018 at Spero Therapeutics, up from -$32000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $645000.0 in Q4 2018 and bottomed at -$497000.0 in Q1 2017.
  • Average Deferred Taxes over 3 years is $44222.2, with a median of -$32000.0 recorded in 2018.
  • Peak annual rise in Deferred Taxes hit 2054.55% in 2018, while the deepest fall reached 105.29% in 2018.
  • Year by year, Deferred Taxes stood at -$28000.0 in 2016, then fell by 17.86% to -$33000.0 in 2017, then soared by 2054.55% to $645000.0 in 2018.
  • Business Quant data shows Deferred Taxes for SPRO at $645000.0 in Q4 2018, -$32000.0 in Q3 2018, and -$23000.0 in Q2 2018.